CIDARA THERAPEUTICS INC

NASDAQ: CDTX (Cidara Therapeutics, Inc.)

最近更新时间: 2天之前, 12:36AM

49.33

2.49 (5.32%)

前收盘价格 46.84
收盘价格 43.77
成交量 3,650,389
平均成交量 (3个月) 386,648
市值 639,800,256
预期市盈率 (P/E Forward) 5.75
价格/销量 (P/S) 1.36
股市价格/股市净资产 (P/B) 4.29
52周波幅
10.14 (-79%) — 56.83 (15%)
利润日期 11 Aug 2025 - 15 Aug 2025
营业利益率 (TTM) -35,743.71%
稀释每股收益 (EPS TTM) -26.68
季度收入增长率 (YOY) -100.00%
总债务/股东权益 (D/E MRQ) 1.89%
流动比率 (MRQ) 3.87
营业现金流 (OCF TTM) -191.84 M
杠杆自由现金流 (LFCF TTM) -81.87 M
资产报酬率 (ROA TTM) -55.20%
股东权益报酬率 (ROE TTM) -299.58%

市场趋势

短期 中期
行业 Biotechnology (US) 看跌 看跌
Biotechnology (全球的) 看跌 看跌
股票 Cidara Therapeutics, Inc. 看涨 看涨

AIStockmoo 评分

-0.4
分析师共识 1.5
内部交易活动 NA
价格波动 -5.0
技术平均移动指标 0.0
技术振荡指标 2.0
平均 -0.38

相关股票

股票 市值 DY P/E(TTM) P/B
CDTX 640 M - - 4.29
RVMD 7 B - - 3.59
AKRO 4 B - - 4.04
CYTK 4 B - - 60.31
RNA 4 B - - 2.71
CRNX 3 B - - 2.28

Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. The Company’s portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak® platform targeting oncologic, viral and autoimmune diseases.

部门 Healthcare
行业 Biotechnology
投资方式 Small Core
内部持股比例 1.74%
机构持股比例 86.20%

所有权

姓名 日期 持有股份
Vivo Capital, Llc 31 Mar 2025 684,276
Vestal Point Capital, Lp 31 Mar 2025 504,542
Ikarian Capital, Llc 31 Mar 2025 248,940
Acuta Capital Partners, Llc 31 Mar 2025 125,708
Aberdeen Group Plc 31 Mar 2025 120,879
52周波幅
10.14 (-79%) — 56.83 (15%)
目标价格波幅
45.00 (-8%) — 75.00 (52%)
75.00 (RBC Capital, 52.04%) 购买
53.50 (8.45%)
45.00 (WBB Securities, -8.78%) 购买
平均值 57.00 (15.55%)
总计 6 购买
平均价格@调整类型 42.18
公司 日期 目标价格 调整类型 价格@调整类型
Guggenheim 24 Jun 2025 68.00 (37.85%) 购买 46.84
16 May 2025 50.00 (1.36%) 购买 25.50
HC Wainwright & Co. 24 Jun 2025 53.00 (7.44%) 购买 46.84
18 Jun 2025 41.00 (-16.89%) 购买 21.31
RBC Capital 24 Jun 2025 75.00 (52.04%) 购买 46.84
23 May 2025 35.00 (-29.05%) 购买 24.28
Needham 23 Jun 2025 54.00 (9.47%) 购买 44.95
04 Jun 2025 36.00 (-27.02%) 购买 24.05
WBB Securities 23 Jun 2025 45.00 (-8.78%) 购买 44.95
JMP Securities 02 Jun 2025 47.00 (-4.72%) 购买 22.67
27 May 2025 47.00 (-4.72%) 购买 24.00
显示更多

该时间范围内无数据。

日期 类型 细节
26 Jun 2025 公告 Cidara Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
24 Jun 2025 公告 Cidara Announces Pricing of Upsized Public Offering of Common Stock
23 Jun 2025 公告 Cidara Therapeutics Announces Positive Topline Results from its Phase 2b NAVIGATE Trial Evaluating CD388, a Non-Vaccine Preventative of Seasonal Influenza
23 Jun 2025 公告 Cidara Announces Proposed Public Offering of Common Stock
15 May 2025 公告 Cidara Therapeutics to Host Virtual R&D Day to Discuss CD388 as a Potential Universal, Once-Per-Flu Season Preventative of Seasonal and Pandemic Influenza on May 22, 2025
13 May 2025 公告 Cidara Therapeutics to Participate in Two Upcoming Investor Conferences
08 May 2025 公告 Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
01 May 2025 公告 Cidara Therapeutics Announces Promotion of Nicole Davarpanah to Chief Medical Officer and Corrina Pavetto to SVP, Clinical Development
30 Apr 2025 公告 Cidara Therapeutics to Participate in The Citizens Life Sciences Conference
24 Apr 2025 公告 Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025
01 Apr 2025 公告 Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
01 Apr 2025 公告 Cidara Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票